REGYNERA(dia)TION is an international, multicenter, ambispective observational patient registry of adults with recurrent gynecologic malignancies after prior radiotherapy who are treated or planned for reirradiation and/or total ablative strategies as part of routine clinical care. The registry does not assign treatment. Radiotherapy technique, dose, systemic therapy, surgery, metastasis-directed therapy, imaging, and follow-up are selected by the treating multidisciplinary team according to local standards and patient-specific factors. The registry will collect harmonized retrospective and prospective data on disease characteristics, prior radiotherapy, recurrence pattern, reirradiation or ablative treatment exposure, response, progression, survival, severe treatment-related morbidity, fistula events, and patient-reported outcomes where available.
Volrustomig Priming Regimens Exploratory Phase II Platform Study
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
This trial is no longer recruiting — here are similar active trials
Matched by cancer type/biomarker, currently recruiting.
In this phase III study, the primary objective is to test with a one-sided significance of 5% whether for the treatment of small cell lung cancer (SCLC) patients, brain MRI surveillance alone is non-inferior in terms of overall survival compared to prophylactic cranial irradiation (PCI) combined with brain MRI surveillance in the entire study population.
The primary objective of this study is to measure efficacy of saruparib + physician's choice of ARPI compared with placebo + ARPI in men with metastatic hormone-sensitive prostate cancer (mHSPC) who have previously received docetaxel chemotherapy or a prostate-specific membrane antigen (PSMA)-directed lutetium-177 radioligand therapy with no evidence of disease progression and PSA ≥ 0.2 ng/mL.
The purpose of this study is to compare the efficacy of zipalertinib versus placebo in participants with early stage resected non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor mutation (EGFRmt).
About the trial
Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Ogólny stan zdrowia pozwalający na aktywność codzienną (bez znacznego pogorszenia)
- •Oczekiwana długość życia co najmniej 12 tygodni
- •Prawidłowe funkcjonowanie narządów wewnętrznych i szpiku kostnego
- •Waga ciała powyżej 35 kg
- •Potwierdzony rozpoznaniem raka płuca (bez drobnych komórek)
- •Brak określonych mutacji genetycznych w komórkach nowotworu
- •Co najmniej jeden widoczny guz nie poddawany wcześniej napromienianiu
✗ Disqualifies
- •Ucisk na rdzeń kręgowy
- •Historia wrodzonego niedoboru odporności
- •Aktywne lub przebyte choroby autoimmunologiczne lub zapalne
- •Przerzuty do mózgu wymagające sterydów lub powodujące objawy
- •Poprzednia chemioterapia lub inne leczenie systemowe tego nowotworu
- •Leczenie chemioterapią w przeszłości, chyba że minęło co najmniej 12 miesięcy
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 130 Years
- Last updated (source)
- September 29, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (63)
Research Site
Los Angeles, United States
Research Site
Chapel Hill, United States
Research Site
Beijing, China
Research Site
Hangzhou, China
Research Site
Jinan, China
Research Site
Yantai, China
Research Site
Zhengzhou, China
Research Site
Bois-Guillaume, France
Research Site
Caen, France
Research Site
Dijon, France
Research Site
Montpellier, France
Research Site
Batumi, Georgia
Research Site
Tbilisi, Georgia
Research Site
Tbilisi, Georgia
Research Site
Tbilisi, Georgia
Research Site
Tbilisi, Georgia
Research Site
Tbilisi, Georgia
Research Site
Athens, Greece
Research Site
Athens, Greece
Research Site
Elaiones, Greece
Research Site
Piraeus, Greece
Research Site
Thessaloniki, Greece
Research Site
Genoa, Italy
Research Site
Meldola, Italy
Research Site
Milan, Italy
Research Site
Naples, Italy
Research Site
Orbassano, Italy
Research Site
Perugia, Italy
Research Site
Rozzano, Italy
Research Site
Udine, Italy
Research Site
Verona, Italy
Research Site
Kuala Lumpur, Malaysia
Research Site
Kuching, Malaysia
Research Site
Perai, Malaysia
Research Site
Lisbon, Portugal
Research Site
Lisbon, Portugal
Research Site
Lisbon, Portugal
Research Site
Porto, Portugal
Research Site
Cluj-Napoca, Romania
Research Site
Craiova, Romania
Research Site
Floreşti, Romania
Research Site
Belgrade, Serbia
Research Site
Seongnam, South Korea
Research Site
Seoul, South Korea
Research Site
Suwon, South Korea
Research Site
A Coruña, Spain
Research Site
Alcorcón, Spain
Research Site
Barcelona, Spain
Research Site
Madrid, Spain
Research Site
Málaga, Spain
Research Site
Pamplona, Spain
Research Site
Santander, Spain
Research Site
Santiago de Compostela, Spain
Research Site
Valencia, Spain
Research Site
Valencia, Spain
Research Site
Geneva, Switzerland
Research Site
Lausanne, Switzerland
Research Site
Winterthur, Switzerland
Research Site
Zurich, Switzerland
Research Site
Changhua, Taiwan
Research Site
New Taipei City, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taipei, Taiwan
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.